Search research articles
Contact Us
Filters
Showing results (181-190 of 386) with videos related to
Page
of 39
Sort By:
Cancer
|
January 6, 2017
Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer
Brandon Bernard, Vinayak Muralidhar, Yu-Hui Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 1996
Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
M A Carducci, J B Nelson, K M Chan-Tack, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
May 22, 2008
Symptoms, supportive care needs, and function in cancer patients: how are they related?
Claire F Snyder, Elizabeth Garrett-Mayer, Julie R Brahmer, et al.
European Urology Oncology
|
April 30, 2024
Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED)
Daniel Sentana-Lledo, Xiangying Chu, David F Jarrard, et al.
Cancer Chemotherapy and Pharmacology
|
April 13, 2007
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
Antonio Jimeno, Michelle A Rudek, Thomas Purcell, et al.
The Prostate
|
September 19, 2020
Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)
Lauren C Harshman, Victoria X Wang, Anis A Hamid, et al.
Urology
|
March 27, 2007
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy
Gopal K Bajaj, Zhe Zhang, Elizabeth Garrett-Mayer, et al.
Bioconjugate Chemistry
|
January 20, 2005
A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation
Kuo-Shyan Lin, Andrew Luu, Kwamena E Baidoo, et al.
Urology
|
January 31, 2004
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action
Mario A Eisenberger, Menachem Laufer, Nicholas J Vogelzang, et al.
PEC Innovation
|
June 26, 2023
Development and pilot test of a physician-focused cancer clinical trials communication training intervention
Susan Eggly, Mark Manning, Nicole Senft, et al.
Page
of 39
Search research articles
Search
Showing results (181-190 of 386) with videos related to
Sort By:
Page
of 39
Cancer
|
January 6, 2017
Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer
Brandon Bernard, Vinayak Muralidhar, Yu-Hui Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 1996
Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
M A Carducci, J B Nelson, K M Chan-Tack, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
May 22, 2008
Symptoms, supportive care needs, and function in cancer patients: how are they related?
Claire F Snyder, Elizabeth Garrett-Mayer, Julie R Brahmer, et al.
European Urology Oncology
|
April 30, 2024
Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED)
Daniel Sentana-Lledo, Xiangying Chu, David F Jarrard, et al.
Cancer Chemotherapy and Pharmacology
|
April 13, 2007
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
Antonio Jimeno, Michelle A Rudek, Thomas Purcell, et al.
The Prostate
|
September 19, 2020
Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)
Lauren C Harshman, Victoria X Wang, Anis A Hamid, et al.
Urology
|
March 27, 2007
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy
Gopal K Bajaj, Zhe Zhang, Elizabeth Garrett-Mayer, et al.
Bioconjugate Chemistry
|
January 20, 2005
A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation
Kuo-Shyan Lin, Andrew Luu, Kwamena E Baidoo, et al.
Urology
|
January 31, 2004
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action
Mario A Eisenberger, Menachem Laufer, Nicholas J Vogelzang, et al.
PEC Innovation
|
June 26, 2023
Development and pilot test of a physician-focused cancer clinical trials communication training intervention
Susan Eggly, Mark Manning, Nicole Senft, et al.
Page
of 39